How many of us are actually in this?
1.2 billion
Women will be in or past menopause by 2030
Roughly one in seven people on the planet. The single largest under-served health demographic, and the one with the most spending power.
WHO · 2024By the numbers
Menopause, sized
honestly.
The figures that frame this conversation, for the woman wondering if it's just her, the workplace wondering if it matters, and the investor wondering if the market is real. Sourced, dated, and meant to be screenshot-able.
For members
If you've wondered whether it's just you, it isn't.
These are the numbers we wish someone had handed us at 42. Not to alarm you. To name the size of what you're walking into so you can prepare for it like the long-haul project it is.
Why is no one talking about the vaginal stuff?
Up to 80%
Of postmenopausal women have genitourinary symptoms (GSM)
Vaginal dryness, urinary urgency, painful sex. Highly treatable, very rarely raised. The most under-treated part of menopause has the worst name.
North American Menopause Society (NAMS) / Menopause Society · 2020When will the hot flashes actually stop?
7.4 years
Median duration of vasomotor symptoms (hot flashes / night sweats)
Not a few months. Not 'just a phase.' For Black women the median is 10.1 years. For most women, longer than they expect.
Study of Women’s Health Across the Nation (SWAN) Study, JAMA Internal Medicine · 2015What if cancer treatment forced me into menopause?
1 in 3
Women experience menopause alongside or after cancer treatment
Surgical, chemo-induced, or hormone-blocking. Often sudden, often severe, often without HRT as an option. A whole pathway hiding inside the broader population.
Macmillan / NHS · 2023Why did it take so long for someone to name this?
4.6 years
Average time from first perimenopause symptoms to diagnosis
Brain fog, anxiety, joint pain, panic, ADHD-like overwhelm, most women see multiple specialists before anyone names it. The diagnostic backlog is structural, not personal.
Newson Health Menopause Society · 2022Why does my anxiety feel different now?
2×
Women are twice as likely as men to develop PTSD
Trauma exposure is more common in men, but post-traumatic stress hits women harder, and new neuroscience shows ovarian hormones are part of why. A 2026 randomized trial found estradiol normally calms threat circuitry in the brain, but that protective effect is blunted in women with a trauma history. The mental-health gap hiding inside the menopause conversation.
PNAS, Stevens et al. · 2026Am I imagining the years I've lost to feeling unwell?
25%
More of their lives women spend in poor health than men
Not shorter lives, sicker ones. Most of that excess sits in the conditions medicine has historically under-studied: menopause, endometriosis, autoimmune, migraine, mental health. The gap is the lever.
McKinsey Health Institute / WEF · 2024Do I really need to think about my bones now?
1 in 2
Women over 50 will break a bone because of osteoporosis
Estrogen drops at menopause, bone loss accelerates fast, and most women find out the hard way, with a wrist or hip fracture. The midlife window is when prevention still works.
Bone Health & Osteoporosis Foundation · 2024Why does so much of the research feel like it wasn't built for me?
1993
The year US law first required women in clinical trials
The NIH Revitalization Act. Before that, most drug efficacy and safety data was built on male bodies and extrapolated. We're still catching up.
NIH Revitalization Act, US Congress · 1993Is it really harder to get treated if you're not wealthy?
3×
Women in the lowest income bracket are far less likely to be offered MHT
Income, education, postcode, and first language all shape who gets a menopause-trained doctor, who gets prescribed hormone therapy, and who gets sent home with 'it's just your age.' UK and US audits keep finding the same gradient: the lower the income or the further from a city, the wider the treatment gap. The biology is the same, the access isn't.
British Menopause Society / NHS Race & Health Observatory · 2023What about women who don't read this in English?
26 languages
Are spoken at home by more than 100,000 women in the UK alone
Most patient-facing menopause information is written in English at a reading age the average adult finds hard, let alone someone navigating a second language under a hot flash. Translation, plain language, and culturally fluent care aren't a 'nice to have', they're the difference between informed choice and being talked at.
ONS Census 2021, language by sex · 2022For partners and employers
The business case writes itself, once you can see it.
If your workforce skews 35–55 and female, this is the demographic curve hiding inside your retention numbers, your DEI gaps, and your leadership pipeline. The cost of inaction shows up in the people who quietly leave.
Are women really leaving jobs over this?
1 in 10
Women have left a job because of menopause symptoms
A further 14% reduced their hours, and 8% didn't apply for promotion. The cost of doing nothing is a leadership pipeline leaking talent at peak career stage.
Fawcett Society / CIPD UK · 2022What does inaction actually cost the economy?
$26.6 billion
US economic cost of unmanaged menopause symptoms per year
Lost work days plus medical expenses. The Mayo Clinic study put productivity loss alone at $1.8B/year in the US.
Mayo Clinic Proceedings · 2023Why does this hit at the worst possible career moment?
47 - 55
Peak career years coincide exactly with peak symptom years
The age window where women are most likely to hit senior leadership is the same window where untreated symptoms drive them out. Workplace policies still mostly pretend otherwise.
Cross-source: SWAN, Fawcett, BMS · 2022Doesn't every workplace already do something about this?
73%
Of women say their workplace offers no menopause support
Even where policies exist, awareness and uptake are low. The opportunity isn't a benefits PDF, it's lived support women actually use.
CIPD · 2023Where does the industry actually sit on women's health?
38%
Of healthcare and life sciences organizations are 'mature' on women's health
Kearney's first cross-sector benchmark across pharma, MedTech, providers, payors, and investors (131 organizations, 30+ indicators). Two thirds of the ecosystem still treats women's health as nascent or developing, not core.
Kearney [w]Health Healthcare & Life Sciences Index · 2026For investors and operators
The market is real, the gap is structural, capital is selective.
Women's health isn't 'emerging' anymore. It's competing for the same disciplined capital as every other category, and the macro tailwinds (regulatory, demographic, technological) are quietly stacking. We track this because the room expects it.
How under-funded is this category, really?
6%
Of all private healthcare investment goes to women's health
Even at a record-high $2.6B in 2024, women's health was still a single-digit slice of total private healthcare investment. For half the population, carrying a disproportionate share of the lifetime disease burden, the mispricing is the opportunity.
Silicon Valley Bank: Innovation in Women's Health 2025 · 2025What size is the menopause-medication opportunity alone?
$120–230B
Estimated annual untapped menopause-medication market
The pharmaceutical opportunity in menopause alone, before you count digital, devices, services, or workplace. Most of it sits in conditions where treatment exists but adoption, access, and prescriber confidence don't.
FemTech Analytics / industry estimates · 2024How fast is FemTech actually growing?
$39B → $97B
Projected FemTech market growth, 2024 to 2030
Roughly 2.5×. Menopause is the fastest-growing slice. Within that, the untapped menopause-medication market alone is estimated at $120–230B per year.
Grand View Research, FemTech Market 2030 · 2024Does investing in women's health actually return?
$1 → $3
Economic return on every dollar invested in women's health
Closing the gap could deliver the equivalent of 137 million women moving into full-time work by 2040. 50% of the women's-health burden falls on women of working age, so the GDP loop is direct. Women also spend ~25% more of their lives in poor health than men.
McKinsey Health Institute / WEF · 2024What does the total addressable market look like?
$600 billion
Projected women's health market by 2027
FemTech alone is $51B and growing >15% YoY. Menopause is the fastest-growing slice, and the most under-funded relative to addressable population.
McKinsey Health Institute · 2024What's the global GDP at stake?
$1 trillion
Annual global GDP uplift if the women's health gap closed
McKinsey's central estimate. Most of that uplift sits in midlife conditions where treatment exists but adoption doesn't.
McKinsey Health Institute / WEF · 2024Where is the R&D pipeline pointing?
~5%
Of healthcare R&D spend goes to female-specific conditions outside oncology
The pipeline is small, the demand is enormous, and the regulatory path is increasingly favourable. This is what 'structural under-investment' looks like in a chart.
WEF / McKinsey · 2024Is the smart capital paying attention?
88% / 72%
PE investors using AI in deal evaluation / prioritising digital transformation
The capital is selective but moving, and it's moving toward data-informed, digitally native, scalable health platforms. Women's health that ships matches the brief.
PwC Global PE Trends · 2025Where are investors weakest on this category?
30% / 1 in 7
Investor maturity on women's health, and how few apply a gender lens
Only 30% of investors show maturity in women's health. Fewer than 25% apply a gender lens in due diligence. Just ~1 in 7 integrate it into value creation. Investors are the weakest link in Kearney's first cross-sector benchmark — the gap, again, is the opportunity.
Kearney [w]Health Healthcare & Life Sciences Index · 2026Where is the $100B sitting, specifically?
$100B
Market opportunity by 2030 across four under-funded areas
BCG sizes the near-term opportunity across cardiovascular disease, osteoporosis, menopause, and Alzheimer's — four conditions where women carry a disproportionate share of the burden and the existing pipeline is thin. Menopause sits at the intersection of all four.
Boston Consulting Group · 2023How thin is the evidence base women's treatments are built on?
5%
Of clinical trials report sex-disaggregated results
Women are prescribed treatments researched primarily in male bodies. Without sex-disaggregated data, dosing, side effects, and efficacy in women remain partly guesswork — a structural reason midlife symptoms get under-treated even when the drug exists.
WEF Women's Health Investment Outlook · 2026About these numbers
Every figure on this page links to the original source, academic study, government dataset, or industry report from a named institution. We don't use stats from press releases or undated infographics. When sources disagree we say so. When new data lands we update the figure and the year. If you spot a number that's gone stale, tell us.
Page last reviewed: May 2026.